Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Corvus Pharma Com (CRVS)

Corvus Pharma Com (CRVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Corvus: Q1 Earnings Snapshot

Corvus: Q1 Earnings Snapshot

CRVS : 2.16 (-0.92%)
Corvus: Q4 Earnings Snapshot

Corvus: Q4 Earnings Snapshot

CRVS : 2.16 (-0.92%)
Corvus: Q3 Earnings Snapshot

Corvus: Q3 Earnings Snapshot

CRVS : 2.16 (-0.92%)
Corvus: Q2 Earnings Snapshot

Corvus: Q2 Earnings Snapshot

CRVS : 2.16 (-0.92%)
Corvus: Q1 Earnings Snapshot

Corvus: Q1 Earnings Snapshot

CRVS : 2.16 (-0.92%)
Corvus: Q4 Earnings Snapshot

Corvus: Q4 Earnings Snapshot

CRVS : 2.16 (-0.92%)
Corvus: Q3 Earnings Snapshot

Corvus: Q3 Earnings Snapshot

CRVS : 2.16 (-0.92%)
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

Prioritizing Development of CPI-818 for T Cell Lymphomas, Autoimmune and Allergic Diseases Plans to Begin Phase 2 Clinical Trial of Ciforadenant in...

CRVS : 2.16 (-0.92%)
Corvus Pharmaceuticals Appoints Dr. James Rosenbaum Senior Vice President of Research

BURLINGAME, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage...

CRVS : 2.16 (-0.92%)
Corvus Pharmaceuticals Provides Program Updates at R&D Symposium

Highlights new interim data from CPI-818 Phase 1/1b study in patients with relapsed T cell lymphomas Program covers scientific rationale, preclinical...

CRVS : 2.16 (-0.92%)

Barchart Exclusives

5 'Pick and Shovel' AI Growth Stocks to Scoop Up Now
With AI demand rising and data centers set for explosive growth, these AI infrastructure providers emerge as prime investment opportunities now. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar